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A B S T R A C T   
β-adrenergic receptor antagonists (β-blockers) are extensively used to improve cardiac performance in heart 
failure (HF), but the electrical improvements with these clinical treatments are not fully understood. The aim of 
this study was to analyze the electrophysiological effects of β-adrenergic system remodeling in heart failure with 
reduced ejection fraction and the underlying mechanisms. We used a combined mathematical model that inte-
grated β-adrenergic signaling with electrophysiology and calcium cycling in human ventricular myocytes. HF 
remodeling, both in the electrophysiological and signaling systems, was introduced to quantitatively analyze 
changes in electrophysiological properties due to the stimulation of β-adrenergic receptors in failing myocytes. 
We found that the inotropic effect of β-adrenergic stimulation was reduced in HF due to the altered Ca2+ dy-
namics resulting from the combination of structural, electrophysiological and signaling remodeling. Isolated cells 
showed proarrhythmic risk after sympathetic stimulation because early afterdepolarizations appeared, and the 
vulnerability was greater in failing myocytes. When analyzing coupled cells, β-adrenergic stimulation reduced 
transmural repolarization gradients between endocardium and epicardium in normal tissue, but was less 
effective at reducing these gradients after HF remodeling. The comparison of the selective activation of 
β-adrenergic isoforms revealed that the response to β2-adrenergic receptors stimulation was blunted in HF while 
β1-adrenergic receptors downstream effectors regulated most of the changes observed after sympathetic stimu-
lation. In conclusion, this study was able to reproduce an altered β-adrenergic activity on failing myocytes and to 
explain the mechanisms involved. The derived predictions could help in the treatment of HF and guide in the 
design of future experiments.   
1. Introduction 
Heart failure (HF) is a major health problem. Patients with reduced 
ejection fraction present weak cardiac performance and have a high risk 
of sudden cardiac death due to ventricular arrhythmias. Many alter-
ations to the myocardium that occur in HF can promote the electrical 
instabilities observed. These include electrophysiological and structural 
remodeling of cardiac tissue, such as changes in the expression and 
function of membrane ion channels and Ca2+-handling proteins. These 
changes can alter action potentials and Ca2+ dynamics and lead to the 
electrical and contractile dysfunction that characterizes failing myo-
cytes [1,2]. Remodeling of signaling cascades, such as Ca2+/calmodulin- 
dependent protein kinase II (CaMKII) and β-adrenergic receptor (β-AR) 
pathways, also plays a crucial role [3,4]. 
Several neurohormonal mechanisms are activated during HF to 
maintain cardiac output, including the sympathetic nervous system, and 
a continuous release of catecholamines provokes a sustained activation 
of cardiac β-ARs. Catecholamine binding to membrane β-AR, a type of G- 
protein-coupled receptor (GPCR), initiates the adenylyl cyclase (AC)/ 
cyclic AMP (cAMP)/ protein kinase A (PKA) signaling cascade. PKA 
phosphorylates several electrophysiological proteins and modulates the 
electrical activity of the heart [5]. In the normal myocardium, this 
sympathetic stimulation increases heart rate and the force of contraction 
to enhance cardiac performance in demanding situations. In the failing 
heart, however, prolonged stimulation becomes detrimental and ulti-
mately contributes to the pathogenesis of HF [6–8]. 
Abbreviations: AP, action potential; β-AR, β-adrenergic receptor; CaT, Ca2+ transient; cav, caveolar signaling domain; cyt, cytosolic signaling domain; ecav, 
extracaveolar signaling domain; HF, Heart failure; iso, isoproterenol; SR, sarcoplasmic reticulum; TDR, transmural dispersion of repolarization. 
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Malignant arrhythmias are the major cause of death among patients 
with HF, and the use of β-blocker agents has demonstrated efficacy in 
reducing mortality rate and improving clinical outcomes [9,10]. 
Although changes in β-ARs and other proteins of the signaling cascade 
have been reported in failing myocytes, most clinical trials quantify the 
survival benefits of β-blocker therapy without going into depth 
regarding the mechanisms by which these drugs prevent arrhythmo-
genesis [11]. The existence of β-AR isoforms (β1 and β2-ARs are the 
major subtypes) with different pathways (e.g. only β2-AR subtypes 
activate inhibitory G-proteins, and β1 receptors are the only direct ef-
fectors on cytosolic protein phosphorylation) has raised questions 
related to variable effectiveness of β-blockers depending on drug affinity 
to the receptors. For instance, non-selective pharmacological agents or 
even partial agonists appear to have greater benefits than selective β1 
antagonists [12–14]. 
Investigations about cAMP signaling have given rise to detailed 
mathematical models of the adrenergic pathways, including signaling 
compartmentation and the interaction with electrophysiological pro-
teins [15–17]. Simulations including these models can improve mech-
anistic insight into HF pathophysiology, but investigations performed to 
date have generally focused on effects of electrical remodeling rather 
than on HF-induced alterations in the β-AR system. The aim of this study 
was to apply β-adrenergic signaling changes according to experimental 
observations of protein function and expression in failing myocytes to 
reproduce the electrophysiological response to β-AR stimulation in HF. 
This approach allows the investigation of the altered signaling mecha-
nisms that trigger electrical instabilities and contractile dysfunction in 
patients with HF with reduced ejection fraction. We integrated existing 
cellular models of signaling and electrophysiology and introduced 
changes in protein expression and localization according to available 
data. These initial results will be useful to understand mechanisms and 
guide future experimental studies aimed at improving clinical HF 
treatments. 
2. Methods 
2.1. Baseline cellular models 
The mathematical model representing a human ventricular myocyte 
included the Heijman et al. β-adrenergic signaling pathway [17] inte-
grated into the ORd action potential model [18], which also considers 
the CaMKII signaling cascade. The complete formulation was initially 
described in [19] to represent a normal epicardial cell. We used an 
improved version of the model [20] which maintained the main char-
acteristics, such as cAMP signal compartmentation and the PKA- 
mediated phosphorylation of eight electrophysiological proteins: L- 
type Ca2+ channel (ICaL), slow delayed rectifier K+ channel (IKs), phos-
pholamban (PLB), troponin I (TnI), ryanodine receptor (RyR), fast Na+
channel (INa), Na+/K+ pump (INaK), and background K+ current (IKb). 
To simulate HF with reduced ejection fraction phenotype (referred 
only as HF from now on), several changes were introduced in the model. 
The electrophysiological part was modified to represent the character-
istic HF modifications at the cellular level, such as ion channel remod-
eling and the loss of T-tubular cellular domains. Heterogeneous HF 
remodeling was implemented as indicated in Gomez et al. [2]: upregu-
lation of the late Na+ current, the Na+/Ca2+ exchanger, the sarco-
plasmic reticulum (SR) Ca2+ leak, and the CaMKII, and downregulation 
of the SR Ca2+ uptake (SERCA), the transient outward and inward 
rectifier K+ currents, the Na+/K+ ATPase current, and the Ca2+ release 
sensitivity via RyRs. Regarding detubulation, several changes were 
introduced following Sanchez-Alonso et al. [21] methodology: (i) L-type 
calcium channels (LTCC), which are predominant in the subspace 
(submembrane space near T-tubules), were redistributed into the crest, 
(ii) half of the dyadic Na+/ Ca2+ exchangers (NCX) were relocated to the 
surface membrane, and (iii) Ca2+ release from the SR was reduced to 
reproduce orphaned RyRs. 
2.2. Signaling remodeling in heart failure 
The formulation of the β-AR signaling model was also modified to 
reproduce the alterations in HF. An extensive review of experimental 
observations is summarized in Table S2. Despite the general agreement 
on the increased or decreased expression and function of proteins, we 
found a wide range of variation and considered it instead of taking a 
fixed value. A better adjustment was performed in several steps, 
described below. 
Fig. 1 summarizes the remodeling in β-adrenergic signaling: β1-ARs 
are downregulated, which reduces β-AR responsiveness; β2-ARs migrate 
from caveolar (cav) to extracaveolar (ecav) domain due to detubulation 
without causing receptor loss; there is G protein-coupled receptor kinase 
(GRK) upregulation, which phosphorylates β-ARs and this desensitiza-
tion implies β-AR loss of function; phosphodiesterase type 4 (PDE4) is 
downregulated, inhibiting less cAMP and promoting PKA- 
phosphorylation; the downregulation of the cytosolic (cyt) inhibitor1 
increases phosphatase type 1 (PP1) activity, which further de-
phosphorylates PLB, decreasing SERCA function. T-tubule degradation 
causing β2-ARs signaling disruption affects ICaL phosphorylation leading 
to new ecav signaling pathways for subsarcolemmal LTCC (ICaLe). 
Additional modifications were performed to differentiate between 
myocardium layers. ORd model already considers transmural hetero-
geneity. We applied different β2-AR protein expression along the 
transmural wall cells, as quantified by Lang et al. [22], to simulate 
endocardial cells in addition to epicardial cells (Table S3). There were 
also transmural differences between normal (β2-ARepi < β2-ARendo) and 
failing myocytes (β2-ARepi > β2-ARendo). Further details of the model can 
be found in the supplemental material. 
The modifications implemented in the signaling model were first of 
all calibrated with experiments [22]. From the literature (Table S2), we 
had a qualitative knowledge about the 5 important HF remodeling 
changes in the β-AR system. To quantify the molecular changes that led 
to HF phenotype, a population of human epicardial failing cells was 
constructed with uniform variability in the signaling parameters. We 
selected the cells that underwent the same electrophysiological varia-
tions as in experiments [22] according to the following criteria: action 
potential duration (APD) and CaT duration (CaTD) in epicardial cells 
upon β-AR stimulation with isoproterenol were reduced compared to the 
non-stimulated cells in a specific range (− 25% < ΔAPD80 < − 13.2% and 
ΔCaTD80 < 0%). 
2.3. Single cell simulations 
2.3.1. β-adrenergic stimulation protocol 
β-AR stimulation was simulated with saturated dose of agonists, i.e. 
the concentration at which the activation of the receptors is maximal so 
that results were dose independent (1 μM). Besides, model equations 
were run until achieve steady-state conditions to ensure the stability of 
signaling variables modulating the electrophysiology. Heijman et al. 
β-adrenergic model [17] was defined for the non-selective agonist 
isoproterenol, although in the formulation the activation of β1 and β2- 
ARs isoforms was differentiated. We performed selective simulations in 
which only one receptor subtype was stimulated as if the other was 
blocked. The use of isoproterenol and specific antagonists is the common 
approach in most of experiments, facilitating the comparison. 
2.3.2. Population of models 
Biological variability is known to be a feature that can vary the 
response of different individuals to the same perturbation such as a drug 
or pathology. For this reason, we considered in this study populations of 
cells instead of only the baseline models. We applied parameter vari-
ability to electrophysiological and β-adrenergic remodeling variables 
with scaling factors following a log-normal distribution (59%–169%). A 
total of 300 different cells were initially generated and calibrated to 
match physiological biomarkers ranges [23]. Medians and interquartile 
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ranges were measured and EADs cases were excluded from calculations 
because of the repolarization abnormalities. 
The statistical analysis was performed using the Wilcoxon rank sum 
test in MATLAB. Parameters differences were statistically significant for 
p-values <0.01. 
2.3.3. Phosphorylation of electrophysiological substrates 
The phosphorylation of each substrate was represented by a fraction 
ranging from 0 (basal PKA-phosphorylation) to 1 (maximum). To study 
the individual electrophysiological effects of phosphorylated proteins, 
we performed a univariate contribution analysis, in which one substrate 
was completely phosphorylated while the others remained at basal 
levels. APD and CaT peak sensitivities to each parameter were then 
quantified for both the N and HF baseline model. Phosphorylation 
fractions resulting from each baseline model with the different modes of 
β-AR stimulation were also analyzed to compare the contribution of 
phosphorylated proteins in each case. 
2.3.4. Electrophysiological indicators 
The last AP and CaT of 300 beats were examined, after assuring the 
stabilization of both the β-adrenergic system and the electrophysiolog-
ical activity. Cellular biomarkers were APD, calculated at 80% and 90% 
of repolarization (APD80 and APD90), CaT peak (CaTmax), CaT duration 
from maximum upstroke to 80% recovery (CaTD80), and the interval 
between electrical and mechanical termination computed as the differ-
ence CaTD80-APD80. All simulations were run at 1 Hz and biomarkers 
were obtained for this frequency. 
2.3.5. Transmural strand simulations 
A one-dimensional cable composed of 166 myocytes was used to 
study the electrical activity and propagation in coupled cells [18] and 
was simulated in Elvira, a software to solve the monodomain equation 
by using the finite element technique of the operator splitting [24]. One 
half of the strand was composed of endocardial cells and the other half of 
epicardial cells. Midmyocardial cells were not used because of their 
controversial behavior [25,26]. Instead, we applied a gradient of 20 cells 
between endocardial and epicardial to smooth the transition. An addi-
tional HF remodeling change considered is the reduction of intercellular 
coupling modeled by a 50% decrease in the diffusion coefficient [2]. To 
avoid edge effects, only the 146 central nodes were considered for cal-
culations. Besides cellular biomarkers, we measured repolarization time 
(RT) along the fiber as time to 90% of repolarization since the initiation 
of the stimulus for each cell. The difference between the maximum and 
minimum RT values indicated the transmural dispersion of 
repolarization (TDR). 
3. Results 
3.1. β-Adrenergic stimulation in heart failure 
In failing myocytes, in addition to the electrophysiological remod-
eling, changes in β-adrenergic signaling proteins may contribute to the 
altered electrophysiology. Therefore, the initial goal was to obtain 
insight into this signaling remodeling by establishing specific changes 
that may best represent the HF phenotype. From previous experimental 
studies, we selected 5 model parameters commonly reported to be 
altered in HF and generated a population in which these were upregu-
lated or downregulated within a defined variability range (Table S2). 
Fig. 2A, showing APs and CaTs from these HF populations, illustrates 
that β-adrenergic stimulation with isoproterenol modulated differently 
the electrophysiological phenotype depending on parameter combina-
tions applied for signaling remodeling (blue traces). The same remod-
eling also affected, to a lower extent, APs and CaTs of cells with no 
β-stimulation (green traces). From these populations we selected cells 
that showed consistency with experiments [22] in the degree of APD and 
CaTD shortening following β-stimulation (Fig. 2B), as described in the 
Methods section. This calibration step was used to define the signaling 
HF remodeling. 
During the calibration, 324 out of the initial 1000 models were 
within the accepted group. Ranges of the 5 signaling parameters in the 
accepted and rejected sets are shown in Fig. 2C. Since differences be-
tween groups were all statistically significant (p < 0.01), we chose the 
median values of the 5 parameters from the accepted models, shown in 
Table 1 as scale factors relative to normal myocytes, to define the basic 
β-adrenergic remodeling in HF. Specifically, this analysis quantitatively 
predicts downregulation of β1-ARs, PDE4 and Inh1, upregulation of GRK 
upregulation, and a decrease in β2-ARs in the cav compartment due to 
their migration to the ecav domain. These changes, together with the 
electrophysiological and structural remodeling in myocytes, constituted 
our baseline HF model. 
3.2. Comparison of β-adrenergic stimulation in normal and failing 
myocytes 
In Fig. 3, the effects of β-adrenergic stimulation with isoproterenol 
are compared in normal and failing myocytes. Fig. 3A represents the AP 
and CaT traces for the baseline models under the four different condi-
tions: N or HF, and with or without isoproterenol. When comparing the 
Fig. 1. β-adrenergic signaling remodeling in 
heart failure (HF). Downregulated proteins: 
isoform β1 adrenoreceptor (β1-AR), phos-
phodiesterase 4 (PDE4) and inhibitor 1 
(Inh1); upregulated proteins: G protein- 
coupled receptor kinase (GRK). Other 
changes: redistribution of β2 adrenoreceptor 
(β2-AR) activity from caveolar (cav) to 
extracaveolar (ecav), L-type Ca2+ channels 
(LTCC) that migrate to the crest are phos-
phorylated by ecav signaling pathways. 
Molecules of cytosolic (cyt) compartment 
are also affected.   
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electrophysiology between normal and failing cells, the characteristic 
long AP and reduced systolic Ca2+ in HF were also observed following 
sympathetic stimulation. In HF, β-adrenergic stimulation produced 
slightly less APD90 shortening (reduction of 12% versus 15% in normal 
myocytes) and a smaller relative increase of CaT amplitude (increase of 
89% versus 108%). 
Population simulations were then conducted to evaluate variability 
in the response to β-stimulation in N and HF myocytes. Inter-individual 
variability in signaling and electrophysiological parameters introduced 
dispersion to each of the studied biomarkers (Fig. S1) and allowed us to 
quantify the vulnerability to repolarization abnormalities in the 
different cases (Fig. 3B). Whereas cells without β-adrenergic stimulation 
were not prone to develop EADs, isoproterenol caused repolarization 
abnormalities. 
Transmural dispersion of repolarization is strongly related to 
arrhythmogenesis, and we therefore analyzed whether there were dif-
ferential effects of β-stimulation in epicardial versus endocardial cells. 
Our simulations showed that endocardial cells were more vulnerable to 
EADs under β-stimulation than epicardial cells, and failing conditions 
increased the probability of EADs development in both types of cells. 
The repolarization difference between endocardial and epicardial cells, 
shown in Fig. 3C and measured as APD90 dispersion (∆APD90endo-epi), 
decreased with isoproterenol for N and HF myocytes similarly. In the 
case of HF, β-adrenergic stimulation counteracted the increase caused by 
failing conditions. Regarding CaT, the increase of Ca2+ peak caused by 
sympathetic stimulation depended on the maximum Ca2+ in control 
conditions. In HF, the depressed CaT was slightly enhanced and the 
increase was smaller in endocardial cells, which have less systolic Ca2+
than epicardial cells. 
The delay between Ca2+ recovery and APD repolarization, quantified 
as (CaTD80-APD80), has been proposed as a biomarker of arrhythmia 
vulnerability [22,23], as delayed afterdepolarizations (DADs) can be 
triggered by the elevated intracellular [Ca2+] after the membrane has 
already repolarized. Fig. 3C shows that β-adrenergic activity shortened 
CaTD-APD interval, thereby presumably reducing the predisposition to 
DADs. Compared to normal conditions in which major reductions of 
CaTD-APD period were obtained after sympathetic stimulation, the 
reduction effect was smaller in HF, especially in endocardial cells. 
Electrophysiological HF remodeling was the cause of the elevated CaTD- 
APD, and this combined to the altered β-adrenergic regulation led to a 
smaller reduction compared with normal cells, and potentially increased 
susceptibility to DADs. 
These results highlight the differential effects of β-AR stimulation on 
N and HF myocytes. Although isoproterenol is protective in N and HF 
conditions by reducing APD dispersion, the impact on decreasing the 
probability of DADs is smaller in HF and the arrhythmogenic risk of HF 
through EADs development increases with β-AR stimulation. Isoproter-
enol also improves CaT in HF but the increase is far from the effect in N 
cells. 
3.3. Selective β-adrenergic stimulation 
The understanding of the relative role of β-AR isoforms on electro-
physiology is crucial to select among a variety of pharmacological 
agents. In HF, β1 isoform is reduced while β2 subtype changes its location 
in the membrane compartments without altering the total number of 
receptors. The differences in the remodeling of β1 and β2 pathways help 
explain the differential roles of both isoforms in the altered electro-
physiological behavior of failing cells. The individual influence of the 
two dominant subtypes on cardiac electrophysiology were examined to 
evaluate potential differences between them and a non-selective 
Fig. 2. Experimental calibration of a β-population of failing (HF) myocytes stimulated with isoproterenol (iso). A) Action potential (AP) and Ca2+ transient (CaT) 
traces of some representative cells of the population with fixed electrophysiological remodeling and variable signaling. The basic HF models (black and red, for iso0 
and iso1 respectively) represent the APs and CaT of myocytes without modifications in the β-adrenergic system. B) Biomarker histograms of the population show 
ΔAPD80 and ΔCaTD80 ranges accepted. C) Signaling parameter distributions divided in accepted and rejected models (*p < 0.01). Results from epicardial cells 
stimulated at 1 Hz. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 1 







Inhibitor1 0.75  
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stimulation. Fig. 4A compares AP and CaT traces in failing myocytes 
under different signaling conditions. The electrophysiological effect of 
the activation of both receptor subtypes simultaneously (β1 + β2, 
equivalent to isoproterenol) was very similar to selective β1-AR stimu-
lation, and differed from selective β2-AR stimulation, which caused only 
minimal changes to membrane potential or intracellular [Ca2+]. 
In Fig. 4C, the population response to β-adrenergic stimulation was 
quantified as the median of the difference of biomarkers between β-ARs 
stimulation and control (without β-AR stimulation) for every cell. 
Negative values indicate a decrease and positive values an increase in 
Fig. 3. β-adrenergic modulation of action potential (AP) and Ca2+ transient (CaT) in normal (N) and failing (HF) myocytes. A) Comparison of AP and CaT traces of 
the baseline epicardial models. B) Quantification of early afterdepolarizations (EADs) cases in N and HF populations of endocardial (endo) and epicardial (epi) cells. 
C) Comparison of transmural APD dispersion (APD90endo-epi), CaT peak (CaTmax) and CaTD80-APD80 interval in the population (median and interquartile range). 
Results from cells stimulated at 1 Hz. 
Fig. 4. Selective β-adrenergic modulation of action potential (AP) and Ca2+ transient (CaT) in heart failure (HF). A) Comparison of AP and CaT traces of the HF 
baseline model. B) Quantification of early afterdepolarizations (EADs) cases in N and HF populations of endocardial (endo) and epicardial (epi) cells. C) Comparison 
of β-isoform effect on APD90, CaT peak (CaTmax) and CaTD80-APD80 interval in the population (median and interquartile range). Results from epicardial cells 
stimulated at 1 Hz. 
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the corresponding biomarker. APD reduction, CaT increase and 
(CaTD80-APD80) decrease were observed with specific β1-AR stimulation 
and this modulation was very similar to the one exerted by isoproter-
enol. This occurred both in HF and N conditions. However, β2-AR 
stimulation provoked changes of less or opposite magnitude (shortening 
instead of prolongation in some cell models). For instance, while β2 
modulation of CaT was half of β1 effect in N myocytes, it was blunted in 
the setting of HF. This minimal impact was also observed in the other 
biomarkers. Surprisingly, while isoproterenol shortened APD, β2 ago-
nists prolonged it in normal myocytes. This prolongation was also 
related to the increased number of EADs with β2-AR stimulation. How-
ever, our results suggest that β2 becomes less proarrhythmic in HF in 
terms of EAD generation, whereas β1 increases the probability of EADs. 
Therefore, the arrhythmogenic effects (EADs) of β-AR stimulation in HF 
are due to the β1-AR subtype, but the activation of β1-AR pathways is 
also the main way to increase Ca2+ levels and reduce the CaTD-APD 
interval via the β-adrenergic system. 
The analysis of EADs to elucidate which β-adrenergic parameters 
contributed to these repolarization abnormalities were not conclusive 
and only electrophysiological properties could be related to this 
phenotype as in previous studies (see supplemental Fig. S3). 
3.4. Mechanisms of β-adrenergic signaling 
The modulation of the electrophysiological activity of car-
diomyocytes by β-AR signaling cascades is mediated by PKA phos-
phorylation of membrane ion channels and Ca2+-handling proteins. A 
contribution analysis of the eight targets subject to phosphorylation was 
performed to quantify their individual impact on APD90 and CaTmax. 
Fig. 5A shows, as percentages, the univariate contribution of each PKA- 
phosphorylated target to APD90 and CaTmax. These were obtained 
through simulations in which the phosphorylation fractions of individ-
ual targets were set to 1 while the others were fixed at 0. IKs turned out to 
be the main modulator of APD shortening, followed by ICaL and INaK with 
prolongation effects. ICaL and PLB were the key factors responsible for 
CaTmax increase under β-AR stimulation. Different values between N and 
HF highlight that electrophysiological remodeling alters the response to 
protein phosphorylation. The most remarkable observation is that ICaL 
impact decreased considerably in HF. This is because ICaL refers only to 
channels PKA-phosphorylated in the cav domain, and it was 
compensated by the contribution of ICaL phosphorylation in the ecav 
domain (ICaLe), as L-type Ca2+ channels distribute in this domain in HF 
due to loss of T-tubules. 
Apart from sensitivities, the activating effect of PKA phosphorylation 
on electrophysiological substrates also depends on the degree of phos-
phorylation. Fig. 5B represents the PKA-phosphorylation level of each 
electrophysiological substrate in N (left) and in HF (right) conditions, 
differentiating between non-selective stimulation (β1+ β2) and selective 
β-AR isoform stimulation (blue, orange and green bars respectively). A 
fraction equal to 1 represents a maximal change in the target protein 
phosphorylation, while 0 represents the baseline phosphorylated state. 
Differences between N and HF are due to β-adrenergic protein remod-
eling in failing myocytes (β1-AR downregulation, GRK upregulation, etc) 
which alter compartmentalization and PKA-phosphorylation activity. 
Maximal phosphorylation fractions were computed under non-selective 
and β1-selective stimulation in normal cells. In HF, a slight decrease in 
the eight original targets was observed, while ICaLe, only present in 
failing cells, increased. In N conditions, saturated selective β2-AR stim-
ulation only led to maximal phosphorylation of caveolar substrates, 
highlighting the local PKA activation produced by β2-ARs. Changes from 
N to HF are more remarkable under β2-selective stimulation because 
extracaveolar phosphorylation of substrates increases and the activation 
tends to be more global. 
This analysis highlights on the one hand, that HF electrophysiolog-
ical remodeling alters phosphorylation impact on AP and CaT, and on 
the other hand that β-adrenergic signaling remodeling, as well as se-
lective β-AR stimulation, changes substrate phosphorylation levels. Both 
systems contribute to the final electrophysiological phenotype of failing 
myocytes. 
3.5. Variability of β-adrenergic signaling 
The introduction of interindividual differences to consider all the 
potential electrophysiological phenotypes provided a wide range of 
biomarkers variability. Fig. 6 illustrates the histograms of biomarkers 
modulation as the difference between β-ARs stimulation and control. 
In this way, all normal myocytes presented APD shortening after β1- 
AR stimulation, but APD prolongation after β2-AR activation. In the case 
of CaTmax, it was increased in all models, the only difference between 
β-ARs was the range of CaTmax variation. In HF, β-adrenergic remodeling 
Fig. 5. Sensitivity analysis of βAR-mediated PKA-phosphorylation. A) APD and CaTmax sensitivities to individual substrate phosphorylation fraction (fprotein) in N and 
HF. B) Comparison of substrate PKA-phosphorylation under saturated selective and non-selective β-stimulation. Signaling compartmentation: caveolar (cav), 
extracaveolar (ecav) and cytosolic (cyt). Results from epicardial cells stimulated at 1 Hz. 
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caused changes in β2-AR modulation effect. Indeed, the increase or 
decrease of APD and CaTmax depended on the remodeling degree of the 
signaling parameters. To go in depth into this phenomenon, populations 
were separated in two groups according to the increase or decrease of 
biomarkers after selective β-AR stimulation (Fig. S2). Then, the contri-
bution to this classification of the 5 signaling parameters remodeled in 
HF was analyzed. Fig. S2 panel A shows that β2-AR and PDE4 controlled 
APD modulation; the strong downregulation of the former shortened it 
(ΔAPD90 < 0) while the strong downregulation of the latter prolonged 
the duration (ΔAPD90 > 0). The analysis of CaTmax in Fig. S2 panel B 
indicates that only strong PDE4 downregulation and weak down-
regulation of inhibitor1 contributed to CaTmax increase (ΔCaTmax > 0). 
Fig. S2 panel C helps explain the similarities between selective β1 and 
non-selective stimulation (iso) by comparing biomarker differences. As 
expected, a strong downregulation of this receptor isoform, as can occur 
in HF, increased the differences between both stimulation protocols, 
highlighting the dominant role of β1-AR in human cardiomyocytes. 
Populations of models indicate that specific changes in the β-AR 
Fig. 6. Interindividual variability in selective βAR stimulation. A) APD and CaT modulation histograms in the normal (N) population. B) APD and CaT modulation 
histograms in the failing (HF) population. Results from epicardial cells stimulated at 1 Hz. 
Fig. 7. Dispersion of repolarization in a transmural strand. Normal (N) vs heart failure (HF) for the different β-adrenoreceptor isoform stimulation conditions.  
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signaling pathway can lead to different β-AR stimulation responses, 
especially with β2-AR. 
3.6. Transmural effects of β-AR stimulation 
Simulations in a multicellular one-dimensional cable including 
endocardial and epicardial cells complemented the unicellular simula-
tions in the different types of cells by adding the effect of cellular 
coupling and transmural electrical propagation. As predicted with APD 
values in cellular simulations, repolarization time, measured as time to 
90% of repolarization since the initiation of depolarization, decreased 
with β-AR stimulation for both N and HF conditions, except for β2-AR in 
normal myocytes (Fig. 7). However, the effect on transmural dispersion 
of repolarization (TDR) differed between strands composed of normal or 
HF myocytes. While isoproterenol and selective β1-AR stimulation 
reduced TDR in the normal strand, β-AR stimulation in HF had only 
minimal effects and would therefore not be beneficial. The control 
strand shows that the electrophysiological modifications and slow con-
duction velocity due to reduced intercellular coupling in HF predispose 
the myocardium to a greater risk of arrhythmia with larger repolariza-
tion times and TDR. The only exception was β2-AR that became less 
arrhythmogenic in HF than in normal myocytes. All in all, what these 
results suggest is that the protective effects of β-AR stimulation (TDR 
reduction) observed in N myocytes disappear in HF. 
4. Discussion 
4.1. Main findings 
The adverse changes in ventricular myocytes during the progression 
of HF lead to electrical instabilities and contractile dysfunction. Ac-
cording to this study, the role of the β-adrenergic system should be 
considered, since the electrophysiological modulation resulting from 
signaling protein remodeling might contribute to arrhythmogenesis. 
Additionally, the electrophysiological response of failing cells to sym-
pathetic stimulation is different to the effects observed with β-agonists in 
normal myocytes, which highlights the need to test pharmacological 
agents under the setting of HF. The present computational study, based 
on the available data to date, predicts that in HF β-AR stimulation (i) 
induces a smaller positive inotropic response compared with that seen in 
normal myocytes, (ii) increases the vulnerability of myocytes to develop 
EADs, (iii) decreases the probability of DADs generation by reducing the 
CaTD-APD interval although, compared to N, HF is less protective, (iv) 
does not provide a beneficial reduction of TDR as observed in N con-
ditions, and (v) is blunted when only β2-AR isoforms are activated. 
4.2. Compartmented PKA-phosphorylation activated by β-adrenergic 
stimulation modulates action potentials and Ca2+ transients 
The β-AR-mediated modulation of AP and CaT determines the elec-
trical activity and contractility of the heart. While the inotropic effect of 
β-AR agonists is widely known [27,28], the exact β-AR-modulation of 
APD is controversial: APD is prolonged [29,30] or reduced [22,31] 
depending on the study. It is to be noted that available data in the 
literature use different experimental protocols, drugs, and species, so 
that a wide variability in the results can be found. In the present study 
we obtained APD and CaTD shortening with isoproterenol as observed in 
ventricular wedge preparations of human hearts [22]. 
The analysis of PKA-phosphorylation degree explained that APD 
shortening resulted from the dominant effect of phosphorylated IKs 
while the increase of CaTmax (equivalent to CaTD shortening) was 
mainly due to the accumulated contribution of ICaL and PLB phosphor-
ylation. Selective β2-AR isoform stimulation had a moderate inotropic 
effect due to the low PKA-phosphorylation of PLB compared to β1-AR 
stimulation, and provoked APD prolongation due to the dominant effect 
of ICaL phosphorylation versus minimal IKs phosphorylation. The 
location of β-ARs subtypes and the compartmentation of the signaling 
cascade were therefore critical factors regulating electrophysiological 
outcomes exerted by β-adrenergic stimulation. It is known that β1-ARs 
are the prominent subtype in cardiomyocytes and generate global cAMP 
signals [27,32], which explains that the regulation mediated by 
isoproterenol and β1-AR stimulation was identical in N conditions. It is 
to be noted that our simulation results showed APD prolongation with 
β2-AR stimulation as opposed to the shortening observed by Lang et al. 
[22]. This discrepancy could be attributed to the fact that the drugs used 
(xamoterol and procaterol) as specific ligands for the activation of 
β-adrenergic isoforms in [22] could have partial specificity [12,33,34]. 
In fact, the effects of isoproterenol (β1 + β2) in our simulations were 
consistent with the experiments, and discrepancies appeared when 
comparing the effects of selective agonists. To see if the model can also 
reproduce the experimental results, a possible scenario of imperfect 
selective isoform activation was simulated and is included in the sup-
plemental material. Results supported the hypothesis of the partial 
specificity offered by the experimental compounds and strengthened the 
contribution of computer models in assessing the effects of β-AR 
stimulation. 
In failing myocytes, signaling remodeling alters PKA- 
phosphorylation and consequently has a different impact on AP and 
CaT, which is also determined by the electrophysiological remodeling. 
IKs phosphorylation seems to be critical to shorten the long APD in 
failing myocytes, which also explains the blunted effect of selective β2- 
AR stimulation. β2-AR stimulation did not cause maximal LTCC phos-
phorylation because cAMP signaling was less localized in the caveolar 
domain after HF remodeling, and part of ICaL phosphorylation effect on 
APD and CaT was translated to the channels relocated in the sarcolemma 
after detubulation. In a recent study, Loucks et al. [35] studied in silico 
the degradation of T-tubular domains by redistributing LTCCs and cAMP 
signaling and showed that channels relocated to the sarcolemmal 
membrane in HF can produce sustained current that increases the risk of 
EADs. Regarding CaT, PLB phosphorylation acts as a compensatory 
mechanism to SERCA downregulation by enhancing SR Ca2+ uptake 
[36,37], but the increase effect on intracellular Ca2+ appears to be 
reduced in HF. 
4.3. Adverse β-adrenergic remodeling effects in HF. Desensitization and 
detubulation 
While sympathetic activity is initially a mechanism to increase 
contractility and maintain cardiac output in HF, the chronic stimulation 
becomes detrimental and initiates a protein remodeling process that 
disrupts the β-adrenergic signaling cascade [38]. Desensitization, 
controlled by PKA and GRK, is initially an adaptive mechanism [39] 
which in HF leads to increased phosphorylation and degradation of 
β-ARs [40]. When we incorporated β1-AR downregulation and GRK 
upregulation in the HF model, decreased cellular cAMP levels provoked 
a reduction in PKA-phosphorylation of substrates with β-agonists in HF 
compared to N and explained the lower inotropy observed [27,41]. A β1- 
AR downregulation higher than 18% (value applied in the baseline 
model of HF) would be realistic in an aggravated HF condition and could 
decrease PKA-phosphorylation to a larger extent, increasing differences 
in the electrophysiological modulation between non-selective and se-
lective β1-AR stimulation. The controversial modifications in the 
inhibitory G-protein (Gi) coupled to β2-AR [22,42,43] during HF were 
not introduced. However, upregulated GRK, which enhanced protein 
function, contributed indirectly to reduce Gi activation. Both PKA and 
GRK compete in the phosphorylation of β-AR. As β2-AR coupling to Gi 
depends on GPCR PKA-phosphorylation, a higher GRK-mediated phos-
phorylation reduced PKA-phosphorylation of receptors and β2-ARs 
coupling to G-protein (Gs) dominated over Gi. These results agree with 
the reduction in PKA-phosphorylation of β2-AR observed in failing 
myocytes and the consequent switch from Gi to Gs activation [22]. 
Nevertheless, the most important remodeling factor altering β2-AR 
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signaling is detubulation. 
Structural and functional remodeling of cellular microdomains leads 
to changes in cAMP compartmentation. β2-AR signaling, which is locally 
confined in T-tubules and regulates LTCC in healthy myocytes, un-
dergoes substantial changes in HF, presumably due to the loss of T- 
tubular microdomains [44,45], which can explain the diminished elec-
trophysiological effects in HF. Other studies highlight though that due to 
the conservation of the total number of β2-AR in HF, these receptors 
remain functional and cause positive inotropy and changes in Ca2+
[27,46,47]. When we introduced all the changes observed in cAMP 
signaling compartmentation [48–50], β2-AR signaling became more 
global and the modulation of APD and CaT decreased. The tight regu-
lation of ICaL by β2-AR in N conditions is weakened in failing myocytes 
because of the reorganization of channels and receptors, contributing to 
the impairment of Ca2+ dynamics. Besides detubulation, PDE down-
regulation also causes changes in the compartmented cAMP and PKA 
signals that affect AP and CaT [45,51]. Cytosolic proteins, such as PLB, 
were not further phosphorylated in HF following β2-AR stimulation as 
DeSantiago et al. observed [46], in part because the enhanced activity of 
PP1 found in failing myocytes due to inhibitor1 downregulation restricts 
PKA activity [52,53], and because β2-ARs still have limited control of 
cytosolic cAMP signals in the model despite applying caveolar signaling 
disruption [54,55]. 
4.4. Arrhythmogenesis in failing myocytes 
Enhanced sympathetic activity has been related to the generation of 
arrhythmias, especially in HF, where the development of EADs and 
DADs has been observed [4,22,29,35,46]. Our simulations confirmed 
that EAD development increased after β-AR stimulation in HF. With 
respect to DAD generation, although our simulations did not show 
DADs, the wider CaTD-APD period in HF compared to control would 
suggest a higher likelihood of DAD development in HF. Previous studies 
have suggested that Ca2+ overload plays a role in afterdepolarization 
formation and that β2-AR stimulation might be the most arrhythmogenic 
factor in HF [4,22,35,46]. Triggered activity caused by DADs were 
observed only during β2-AR stimulation in human wedge preparations of 
failing hearts, which were attributed to transmural differences in CaT 
and APD generated after HF remodeling [22]. By contrast, in our sim-
ulations, both the inotropic effects of β2-AR stimulation and the apparent 
arrhythmia susceptibility were reduced in HF compared with normal 
cells and tissues. These discrepancies could be due to the partial speci-
ficity of β-agonists used in experiments versus the theoretical approach 
in which only one β-AR subtype is activated while the other is 
completely blocked. In N conditions, EADs resulting from sympathetic 
stimulation are driven by APD prolongation due to ICaL enhancement 
resulting from PKA-phosphorylation, but none of the β-AR system 
related factors was significant. This finding was also observed in the 
computational study of Loucks et al. [35], with the mechanistic differ-
ence that EADs were induced in failing myocytes after T-tubular 
disruption and the consequent redistribution of LTCC, which then led to 
enhanced phosphorylation after β2-AR activation. Even though our HF 
model also considered detubulation, a reduced ICaL phosphorylation by 
β2-AR stimulation was observed, and β1-AR was the primary factor 
responsible for ICaL enhancement and EAD development. 
4.5. Transmural gradients 
The heterogeneous signaling and electrophysiological HF remodel-
ing in the different transmural myocytes did not result in significant 
modulation of the different biomarkers in epicardial versus endocardial 
cells under β-AR stimulation. Unidimensional cable simulations were 
then performed to take into account additional factors such as inter-
cellular coupling and electrical propagation in transmural gradients. 
The initial unicellular study revealed that the main differences between 
endocardial and epicardial myocytes observed in N conditions were 
maintained in HF, despite slight differences in the modulation of some 
biomarkers, such as CaTD-APD. Contractility seems to be therefore 
affected throughout the transmural wall in HF. An important difference 
was the larger propensity of endocardial cells to develop EADs due to 
their longer APD compared to epicardial cells. These cells might be the 
origin of triggered activity driven by elevated intracellular Ca2+ and the 
subsequent reactivation of ICaL during a long AP. 
The existence of transmural heterogeneities of repolarization, which 
are common in HF, can create a substrate for arrhythmias [56]. In 
contrast to the increase of transmural dispersion exerted by β-adrenergic 
stimulation in failing myocytes observed by Lang et al. [22], we 
observed only minimal β-adrenergic induced changes to TDR in HF. 
Moreover, β-AR stimulation TDR reduction benefits obtained in a N fiber 
following β1-selective and non-selective stimulation were not present in 
HF. In most circumstances, however, TDR was greater in HF strands than 
in normal strands due to HF-induced electrophysiological remodeling 
and reduction in intracellular coupling that accompanies HF. In view of 
these results, it can be concluded that the increase of spatial gradients 
underlying the development of malignant ventricular arrhythmias in HF 
patients [57], are mainly due to ionic remodeling rather than to β-AR 
stimulation. 
4.6. Clinical implications 
Long-term β-blockers therapy is currently recommended for patients 
with HF to improve symptoms, reduce hospitalizations, and decrease 
mortality rate [10]. In addition to β-AR blockade, antagonist agents can 
have other properties such as antioxidant, anti-inflammatory, and vas-
odilating effects that contribute to their efficacy [13,58]. Based on the 
antiarrhythmic impact, which is the main cause of sudden cardiac death 
in the short term, this study suggests that β1-AR blockade in HF, with 
selective or non-selective drugs, would be protective by reducing EAD 
events. A decrease in spatial repolarization gradients induced by 
β-blockade would also in principle be beneficial, but our results did not 
show such an effect in HF. Although previous experimental and 
computational investigations have suggested specific β2-AR blockers to 
stop the detrimental effects of HF [22,35,46], we could not attribute 
arrhythmogenesis to β2-ARs because of the diminished contribution in 
failing myocytes. 
The benefits of β-AR antagonists have been observed in different 
cardiac pathologies (atrial fibrillation, long QT syndrome, myocardial 
infarction, among others) and explain their extended clinical use 
[59,60]. In atrial fibrillation, β-blockers are used for ventricular rate 
control and, despite not being the most effective antiarrhythmic ther-
apy, they may be helpful for atrial fibrillation prevention under certain 
circumstances, such as reduced ejection fraction [60,61]. A recent 
exception found is the beneficial effect of β-AR stimulation restoration to 
reduce alternans in the postinfarction border zone reported by Tomek 
et al. [62]. Unlike the response of HF myocytes to β-AR stimulation, the 
antiarrhythmic effect of hyperinnervation after myocardial infarction 
could be due to a different remodeling in the border zone. But apart from 
the controversy, the aforementioned study, that combined experiments 
with simulations, also highlighted the potential of computational 
modeling in investigating mechanistic implications. 
An alternative to β-blocker therapy would be the resensitization of 
the β-AR system to restore the beneficial effects of sympathetic stimu-
lation, such as inotropic increase and reduction of TDR. Gene therapy, 
although in its early stages, can act directly on the known molecular 
targets that are altered in HF [63]. The observations of β-AR down-
regulation in HF led investigators to examine whether β1-AR or β2-AR 
overexpression was beneficial. Reactivation of β1-ARs increases 
contractility initially but in the long term causes cardiac hypertrophy 
and fibrosis that contributes to lethal arrhythmias as well as cell death 
[38,64]. Whether β2-AR overexpression improves cardiac function or 
not is still debated, but long term stimulation of β2-ARs does not have 
cardiotoxic consequences [38,65]. Another approach proposed after 
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finding that elevated GRK activity led to dysfunctional β-AR in HF is 
GRK inhibition. At least in transgenic mice, this intervention has 
reduced ventricular dysfunction and is considered a promising therapy 
[38,66]. Similarly, the increase of inhibitor1 levels would also constitute 
a potential target to reduce PP1 inhibition function and ultimately in-
crease SERCA activity. This last strategy, targeted to a specific signaling 
compartment, could increase therapeutic efficacy compared with drugs 
that affect global signaling, because different pathways and remodeling 
of the β-AR microdomains in myocytes determine PKA-phosphorylation 
and cardiac outcomes in HF [60,67]. 
4.7. Limitations 
Our HF model reproduced the main changes in the β-AR system that 
have routinely been observed experimentally. Human data were 
included when available, but most data rely on experiments performed 
in animal models of HF. The comparison with the experimental cardiac 
response to sympathetic stimulation in human failing preparations 
highlights that additional experiments would be crucial to confirm our 
predictions. On the one hand, a consistent methodology for all experi-
ments would facilitate the comparison of selective β-AR isoform stimu-
lation results. The specificity of β-AR agonists is under debate and it 
would be interesting to know if their mechanism of action is equivalent 
to non-specific stimulation with β-blockers. On the other hand, despite 
the increasing research on β-AR stimulation in patients with HF, clinical 
trials do not provide enough information to validate signaling mecha-
nisms. The scarcity of human data entails the dependence on other 
species at the molecular level, which might be the cause of the dis-
crepancies between the mathematical model and experimental obser-
vations. β-AR system model with minor modifications was able to match 
human β-AR stimulation results with isoproterenol, but not the results 
obtained with isoform-specific stimulation. Additional parameters of the 
model should be readjusted to adapt the original canine β-AR model to 
human and for that, reliable electrophysiological responses would be 
required to confirm the results. Afterwards, additional signaling 
pathways such as muscarinic receptor interactions or additional proteins 
prone to PKA-phosphorylation could also help improve the model and 
the electrophysiological properties following sympathetic stimulation. 
An additional limitation is the sympathetic stimulus used to activate 
β-AR with ligands, which has been simplified according to the available 
data and was sufficient for the purpose of the present study. Thus, 
sympathetic innervation was considered homogeneous instead of 
transmurally heterogeneous as some studies have shown [68] and 
agonist concentration was time-independent, fixed at saturated dose of 
maximal stimulation. 
Despite some discrepancies with experimental observations, this 
work presents the most complete relation to date between β-AR 
signaling mechanisms and HF remodeling in single cardiac myocytes 
and transmural cellular strands. The mechanistic investigation of the 
effects in failing cardiomyocytes can help to predict the critical settings 
for lethal arrhythmias and guide in the search of potential molecular 
targets. However, additional experiments to support or refute model 
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